New Combination Anti-Diabetic Drug is Ready to Go: What do You Think?
False
Diabetes
New Combination Anti-Diabetic Drug is Ready to Go: What do You Think?
Discuss any aspect of type I or type II diabetes mellitus here
Hello Fellows: A combination of the generics Atorvastatin and Metformin extended release is ready to go into the market. The bioequivalence of the combination is OK, as shown by this study: Pharmacoki
0
Cat:OpenClinicalForum:209c1fee-a6e1-4cf9-9bd5-7d4dd5443e39
Cat:OpenClinicalForum:209c1fee-a6e1-4cf9-9bd5-7d4dd5443e39Discussion:9bae489b-ece1-4ace-b9ac-0b6a521bae1d
Forums » Open clinical » Diabetes » New Combination Anti-Diabetic Drug is Ready to Go: What do You Think?
Forums
»
Open clinical
»
Diabetes
»
New Combination Anti-Diabetic Drug is Ready to Go: What do You Think?
|
New Combination Anti-Diabetic Drug is Ready to Go: What do You Think?
posted at 2/11/2011 12:26 PM GMT
on bmj.com
|
Posts: 367
First: 13/4/2011 Last: 16/5/2012 |
Hello Fellows: A combination of the generics Atorvastatin and Metformin extended release is ready to go into the market. The bioequivalence of the combination is OK, as shown by this study: Pharmacokinetics of a Fixed-Dose Combination of Atorvastatin and Metformin Extended Release versus Concurrent Administration of Individual Formulations: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single-Dose, Crossover, Bioequivalence Study.Clinical Drug Investigation: 1 December 2011 - Volume 31 - Issue 12 - pp 853-863 Conclusion: Atorvastatin/metformin ER 10 mg/500 mg FDC has similar bioavailability to the co-administration of separate atorvastatin 10 mg and metformin 500 mg tablets. The FDC tablets show similar safety and tolerability profiles to their individual components. Therefore, atorvastatin/metformin ER 10 mg/500 mg FDC tablets can be used safely in clinical settings to decrease the pill burden and increase patient compliance with therapy. I can forsee many diabetic patients getting into better cardiovascular risk, metabolic, and hypelipidaemia control with a much lower number of pills. Do you agree? All Best, Joey |
|
Re: New Combination Anti-Diabetic Drug is Ready to Go: What do You Think?
posted at 2/11/2011 1:22 PM GMT
on bmj.com
|
Posts: 142
First: 29/4/2011 Last: 14/5/2012 |
Steve Lichter published a nice summary of the use of drug combinations in diabetes, hypertension and hyperlipidemia Clinical Diabetes October 2003 vol. 21 no. 4 175-178 Combination Medications in Diabetes Care: An Opportunity That Merits More Attention Steven B. Leichter, MD, FACP, FACE and Stephanie Thomas, CRC During the past few years, new pills have been marketed that are combinations of two separate medications. At present, these products apply to three specific treatment areas related to diabetes: diabetes itself, lipidemia, and hypertension ( Table 1 ). Until recently, the only combination pills on the market for these disease states were combinations of diuretics and one other blood pressure medication. In the past few years, a number of newer combination diabetes and lipid medications have been released, starting with metformin-glyburide, metformin-glipizide, metformin-rosiglitazone, and lovastatin-niacin. More combinations are planned. In all cases, these combination medications are mixtures of two existing drugs that have already been marketed. In all cases thus far, providers have had extensive opportunities to gain experience with both of the combined drugs as single agents, as well as moderate experience in combining them to treat more resistant cases. Clearly, a primary motive for developing and marketing the combination tablet has been economic—an effort by the manufacturer either to extend the patent life and profitability of the key agent in the combination because patent protection was about to expire or to create a new market for an agent that would perform better than the single-agent competition. Although the economic motives for the introduction of combination products seem understandable, the benefits of these combination agents for patients and providers have not been explored in detail. One possibility, that these drugs improve patient adherence to treatment by eliminating one pill in the polypharmacy many patients face, 1 has recently been challenged. 2 A new study in the journal Diabetes Care suggests that, in contrast to other patient populations, 3 diabetic patients do not have a reduction in adherence to their medical regimen when multiple medications are prescribed. If true, this eliminates one possible benefit of combination medications. If there is no … |
|
|
Re: New Combination Anti-Diabetic Drug is Ready to Go: What do You Think?
posted at 21/4/2012 8:27 PM BST
on bmj.com
|
Posts: 504
First: 27/3/2012 Last: 16/5/2012 |
Whatever the results of the study may be, I would not prefer to follow or to prescribe such irrational combination to the diabetic patients. Many of such studies are found nowadays which seem to be businesses oriented. |
Forums » Open clinical » Diabetes » New Combination Anti-Diabetic Drug is Ready to Go: What do You Think?
